1
|
Menne F, Henzen NA, Sollberger M, Monsch AU, Schipke CG. Influence of preanalytical and analytical factors on the quantification of six regulatory serum proteins. Bioanalysis 2023; 15:1157-1167. [PMID: 37650497 DOI: 10.4155/bio-2023-0132] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/01/2023] Open
Abstract
Background: We analyzed differences in protein concentrations in human blood serum depending on the tube material and the immunoassay platform used. Materials & methods: Blood samples from study participants were collected in glass and polypropylene tubes (n = 292). Serum concentrations of six proteins (BDNF, IGF-1, VEGF-A, TGF-β1, MCP-1 and IL-18) were assessed by using ELISAs (all biomarkers), as well as a novel fully automated immunoassay platform (all but IGF-1, n = 211). Bland-Altman analyses were conducted to investigate intrasample variability of protein concentrations. Results: Tube comparison resulted in mean biases of between -0.45 and -70.64%. Platform comparison revealed mean biases of between 21.04 and -128.10%. Conclusion: Protein concentrations can vary significantly depending on the types of tube and immunoassay used, with protein-specific differences.
Collapse
Affiliation(s)
- Felix Menne
- Predemtec AG, Rudower Chaussee 29, 12489, Berlin, Germany
| | - Nicolas A Henzen
- Memory Clinic, University Department of Geriatric Medicine FELIX PLATTER, Burgfelderstrasse 101, 4055, Basel, Switzerland
| | - Marc Sollberger
- Memory Clinic, University Department of Geriatric Medicine FELIX PLATTER, Burgfelderstrasse 101, 4055, Basel, Switzerland
| | - Andreas U Monsch
- Memory Clinic, University Department of Geriatric Medicine FELIX PLATTER, Burgfelderstrasse 101, 4055, Basel, Switzerland
| | | |
Collapse
|
2
|
Boeddrich A, Haenig C, Neuendorf N, Blanc E, Ivanov A, Kirchner M, Schleumann P, Bayraktaroğlu I, Richter M, Molenda CM, Sporbert A, Zenkner M, Schnoegl S, Suenkel C, Schneider LS, Rybak-Wolf A, Kochnowsky B, Byrne LM, Wild EJ, Nielsen JE, Dittmar G, Peters O, Beule D, Wanker EE. A proteomics analysis of 5xFAD mouse brain regions reveals the lysosome-associated protein Arl8b as a candidate biomarker for Alzheimer's disease. Genome Med 2023; 15:50. [PMID: 37468900 PMCID: PMC10357615 DOI: 10.1186/s13073-023-01206-2] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Accepted: 06/22/2023] [Indexed: 07/21/2023] Open
Abstract
BACKGROUND Alzheimer's disease (AD) is characterized by the intra- and extracellular accumulation of amyloid-β (Aβ) peptides. How Aβ aggregates perturb the proteome in brains of patients and AD transgenic mouse models, remains largely unclear. State-of-the-art mass spectrometry (MS) methods can comprehensively detect proteomic alterations, providing relevant insights unobtainable with transcriptomics investigations. Analyses of the relationship between progressive Aβ aggregation and protein abundance changes in brains of 5xFAD transgenic mice have not been reported previously. METHODS We quantified progressive Aβ aggregation in hippocampus and cortex of 5xFAD mice and controls with immunohistochemistry and membrane filter assays. Protein changes in different mouse tissues were analyzed by MS-based proteomics using label-free quantification; resulting MS data were processed using an established pipeline. Results were contrasted with existing proteomic data sets from postmortem AD patient brains. Finally, abundance changes in the candidate marker Arl8b were validated in cerebrospinal fluid (CSF) from AD patients and controls using ELISAs. RESULTS Experiments revealed faster accumulation of Aβ42 peptides in hippocampus than in cortex of 5xFAD mice, with more protein abundance changes in hippocampus, indicating that Aβ42 aggregate deposition is associated with brain region-specific proteome perturbations. Generating time-resolved data sets, we defined Aβ aggregate-correlated and anticorrelated proteome changes, a fraction of which was conserved in postmortem AD patient brain tissue, suggesting that proteome changes in 5xFAD mice mimic disease-relevant changes in human AD. We detected a positive correlation between Aβ42 aggregate deposition in the hippocampus of 5xFAD mice and the abundance of the lysosome-associated small GTPase Arl8b, which accumulated together with axonal lysosomal membranes in close proximity of extracellular Aβ plaques in 5xFAD brains. Abnormal aggregation of Arl8b was observed in human AD brain tissue. Arl8b protein levels were significantly increased in CSF of AD patients. CONCLUSIONS We report a comprehensive biochemical and proteomic investigation of hippocampal and cortical brain tissue derived from 5xFAD transgenic mice, providing a valuable resource to the neuroscientific community. We identified Arl8b, with significant abundance changes in 5xFAD and AD patient brains. Arl8b might enable the measurement of progressive lysosome accumulation in AD patients and have clinical utility as a candidate biomarker.
Collapse
Affiliation(s)
- Annett Boeddrich
- Neuroproteomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany
| | - Christian Haenig
- Neuroproteomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany
| | - Nancy Neuendorf
- Neuroproteomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany
| | - Eric Blanc
- Core Unit Bioinformatics, Berlin Institute of Health at Charité - University Medicine Berlin, Charitéplatz 1, 10117, Berlin, Germany
| | - Andranik Ivanov
- Core Unit Bioinformatics, Berlin Institute of Health at Charité - University Medicine Berlin, Charitéplatz 1, 10117, Berlin, Germany
| | - Marieluise Kirchner
- Core Unit Proteomics, Berlin Institute of Health at Charité - University Medicine Berlin, Lindenberger Weg 80, 13125, Berlin, Germany
| | - Philipp Schleumann
- Neuroproteomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany
| | - Irem Bayraktaroğlu
- Neuroproteomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany
| | - Matthias Richter
- Advanced Light Microscopy, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany
| | - Christine Mirjam Molenda
- Advanced Light Microscopy, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany
| | - Anje Sporbert
- Advanced Light Microscopy, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany
| | - Martina Zenkner
- Neuroproteomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany
| | - Sigrid Schnoegl
- Neuroproteomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany
| | - Christin Suenkel
- Systems Biology of Gene Regulatory Elements, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany
| | - Luisa-Sophie Schneider
- Department of Psychiatry, Charité - University Medicine Berlin, Hindenburgdamm 30, 12203, Berlin, Germany
| | - Agnieszka Rybak-Wolf
- Systems Biology of Gene Regulatory Elements, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany
| | - Bianca Kochnowsky
- Department of Psychiatry, Charité - University Medicine Berlin, Hindenburgdamm 30, 12203, Berlin, Germany
| | - Lauren M Byrne
- UCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK
| | - Edward J Wild
- UCL Huntington's Disease Centre, UCL Queen Square Institute of Neurology, Queen Square, London, WC1N 3BG, UK
- National Hospital for Neurology & Neurosurgery, Queen Square, London, WC1N 3BG, UK
| | - Jørgen E Nielsen
- Neurogenetics Clinic & Research Lab, Danish Dementia Research Centre, Rigshospitalet, University of Copenhagen, Section 8008, Inge Lehmanns Vej 8, 2100, Copenhagen, Denmark
| | - Gunnar Dittmar
- Core Unit Proteomics, Berlin Institute of Health at Charité - University Medicine Berlin, Lindenberger Weg 80, 13125, Berlin, Germany
- Proteomics of Cellular Signalling, Luxembourg Institute of Health, 1a Rue Thomas Edison, 1445, Strassen, Luxembourg
| | - Oliver Peters
- Department of Psychiatry, Charité - University Medicine Berlin, Hindenburgdamm 30, 12203, Berlin, Germany
- German Center for Neurodegenerative Diseases (DZNE), Charitéplatz 1, 10117, Berlin, Germany
| | - Dieter Beule
- Core Unit Bioinformatics, Berlin Institute of Health at Charité - University Medicine Berlin, Charitéplatz 1, 10117, Berlin, Germany
| | - Erich E Wanker
- Neuroproteomics, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Robert-Rössle-Straße 10, 13125, Berlin, Germany.
| |
Collapse
|
3
|
Ren AH, Diamandis EP, Kulasingam V. Uncovering the Depths of the Human Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein Detection and Quantification. Mol Cell Proteomics 2021; 20:100155. [PMID: 34597790 PMCID: PMC9357438 DOI: 10.1016/j.mcpro.2021.100155] [Citation(s) in RCA: 41] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Revised: 09/01/2021] [Accepted: 09/25/2021] [Indexed: 12/20/2022] Open
Abstract
Probing the human proteome in tissues and biofluids such as plasma is attractive for biomarker and drug target discovery. Recent breakthroughs in multiplex, antibody-based, proteomics technologies now enable the simultaneous quantification of thousands of proteins at as low as sub fg/ml concentrations with remarkable dynamic ranges of up to 10-log. We herein provide a comprehensive guide to the methodologies, performance, technical comparisons, advantages, and disadvantages of established and emerging technologies for the multiplexed ultrasensitive measurement of proteins. Gaining holistic knowledge on these innovations is crucial for choosing the right multiplexed proteomics tool for applications at hand to critically complement traditional proteomics methods. This can bring researchers closer than ever before to elucidating the intricate inner workings and cross talk that spans multitude of proteins in disease mechanisms.
Collapse
Affiliation(s)
- Annie H Ren
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada
| | - Eleftherios P Diamandis
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada; Department of Clinical Biochemistry, University Health Network, Toronto, Canada
| | - Vathany Kulasingam
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada; Department of Clinical Biochemistry, University Health Network, Toronto, Canada.
| |
Collapse
|
4
|
Fuentes M, Schipke CG, Freiesleben SD, Klostermann A, Peters O. Presenilin 1 Gene Mutation (M139V) in a German Family with Early-Onset Alzheimer's Disease: A Case Report. Arch Clin Neuropsychol 2021; 37:521-530. [PMID: 34427587 DOI: 10.1093/arclin/acab070] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/02/2021] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVE This study describes a 44-year-old German male with early-onset Alzheimer's disease as a result of a M139V presenilin 1 mutation. The patient has at least seven affected family members, spanning at least four generations. METHOD We performed a complete demographic, genetic, neuropsychological, neuropsychiatric, neuroradiological, and neuropathological characterizations of this patient. The findings were compared with previous reports of patients with the same mutation. Demographic, neuropsychological, neuropsychiatric, neuroradiological, and neuropathological data from several affected members of the patient's family were also addressed. RESULTS We describe similarities shared with other cases, including age at onset, rapid disease progression, severe deficits in arithmetic and visuo-constructive abilities with relative preservation of naming skills, and the presence of predominant frontal behavioral symptoms. Differences with respect to previously described cases, including the absence of positive neurological or radiological findings, psychotic symptoms, or a depressive disorder, are also identified and discussed. CONCLUSIONS Heterogeneity in symptoms between affected patients from the same or from different families suggests that individual, genetic, or epigenetic factors most likely modulate the phenotype of patients carrying the M139V mutation.
Collapse
Affiliation(s)
- Manuel Fuentes
- Department of Psychiatry, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.,German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
| | - Carola G Schipke
- Department of Psychiatry, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Silka Dawn Freiesleben
- Department of Psychiatry, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.,German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
| | - Arne Klostermann
- Department of Psychiatry, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Oliver Peters
- Department of Psychiatry, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.,German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
| |
Collapse
|
5
|
Menne F, Schipke CG, Klostermann A, Fuentes-Casañ M, Freiesleben SD, Bauer C, Peters O. Value of Neuropsychological Tests to Identify Patients with Depressive Symptoms on the Alzheimer's Disease Continuum. J Alzheimers Dis 2021; 78:819-826. [PMID: 33074230 PMCID: PMC7739969 DOI: 10.3233/jad-200710] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Background: Depressive symptoms often co-occur with Alzheimer’s disease (AD) and can impact neuropsychological test results. In early stages of AD, disentangling cognitive impairments due to depression from those due to neurodegeneration often poses a challenge. Objective: We aimed to identify neuropsychological tests able to detect AD-typical pathology while taking into account varying degrees of depressive symptoms. Methods: A battery of neuropsychological tests (CERAD-NP) and the Geriatric Depression Scale (GDS) were assessed, and cerebrospinal fluid (CSF) biomarkers were obtained. After stratifying patients into CSF positive or negative and into low, moderate, or high GDS score groups, sensitivity and specificity and area under the curve (AUC) were calculated for each subtest. Results: 497 participants were included in the analyses. In patients with low GDS scores (≤10), the highest AUC (0.72) was achieved by Mini-Mental State Examination, followed by Constructional Praxis Recall and Wordlist Total Recall (AUC = 0.714, both). In patients with moderate (11–20) and high (≥21) GDS scores, Trail Making Test-B (TMT-B) revealed the highest AUCs with 0.77 and 0.82, respectively. Conclusion: Neuropsychological tests showing AD-typical pathology in participants with low GDS scores are in-line with previous results. In patients with higher GDS scores, TMT-B showed the best discrimination. This indicates the need to focus on executive function rather than on memory task results in depressed patients to explore a risk for AD.
Collapse
Affiliation(s)
- Felix Menne
- German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
| | - Carola Gertrud Schipke
- Charité - Universitätsmedizin Berlin, Experimental and Clinical Research Center, Berlin, Germany
| | - Arne Klostermann
- Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, CBF, Berlin, Germany
| | | | - Silka Dawn Freiesleben
- Charité - Universitätsmedizin Berlin, Experimental and Clinical Research Center, Berlin, Germany
| | | | - Oliver Peters
- German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany.,Charité - Universitätsmedizin Berlin, Experimental and Clinical Research Center, Berlin, Germany.,Charité - Universitätsmedizin Berlin, Department of Psychiatry and Psychotherapy, CBF, Berlin, Germany
| |
Collapse
|
6
|
Value of a Panel of 6 Serum Biomarkers to Differentiate Between Healthy Controls and Mild Cognitive Impairment Due to Alzheimer Disease. Alzheimer Dis Assoc Disord 2020; 34:318-324. [PMID: 32649324 DOI: 10.1097/wad.0000000000000397] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
BACKGROUND There is considerable evidence suggesting that inflammatory responses may be involved in the neurodegenerative cascade of Alzheimer disease (AD). Blood-based biomarker analysis of inflammatory markers indicative of dementia could serve as a minimally invasive and easy-to-administer diagnostic tool in primary care. MATERIAL AND METHODS The authors quantified 6 markers (brain-derived neurotrophic factor, insulin-like growth factor 1, vascular endothelial growth factor, transforming growth factor-beta type 1, monocyte chemoattractant protein 1, and interleukin-18) in blood serum of 68 healthy blood donors (controls), 42 patients with AD at the dementia stage, 55 patients with AD at the stage of mild cognitive impairment (MCI-AD), and 25 patients with MCI non-AD. All patients have been fully characterized, including AD biomarker analyses in cerebrospinal fluid. Data were analyzed in an algorithm that was trained, validated, and then used for dichotomous classification of unknown data into data sets suspicious and not suspicious of AD. RESULTS Using this algorithm, 47 of 55 MCI-AD (85.5%) and 20 of 25 MCI non-AD (80%) cases were classified as suspicious of AD. CONCLUSIONS This panel of 6 markers in blood serum may indicate underlying neurodegenerative processes in patients with AD at the MCI stage. The authors assume that a deranged equilibrium of neuroprotective and inflammatory processes is an overall major cause for neurodegeneration and cognitive decline.
Collapse
|
7
|
Bader JM, Geyer PE, Müller JB, Strauss MT, Koch M, Leypoldt F, Koertvelyessy P, Bittner D, Schipke CG, Incesoy EI, Peters O, Deigendesch N, Simons M, Jensen MK, Zetterberg H, Mann M. Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer's disease. Mol Syst Biol 2020; 16:e9356. [PMID: 32485097 PMCID: PMC7266499 DOI: 10.15252/msb.20199356] [Citation(s) in RCA: 139] [Impact Index Per Article: 34.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2019] [Revised: 04/29/2020] [Accepted: 04/30/2020] [Indexed: 12/15/2022] Open
Abstract
Neurodegenerative diseases are a growing burden, and there is an urgent need for better biomarkers for diagnosis, prognosis, and treatment efficacy. Structural and functional brain alterations are reflected in the protein composition of cerebrospinal fluid (CSF). Alzheimer's disease (AD) patients have higher CSF levels of tau, but we lack knowledge of systems-wide changes of CSF protein levels that accompany AD. Here, we present a highly reproducible mass spectrometry (MS)-based proteomics workflow for the in-depth analysis of CSF from minimal sample amounts. From three independent studies (197 individuals), we characterize differences in proteins by AD status (> 1,000 proteins, CV < 20%). Proteins with previous links to neurodegeneration such as tau, SOD1, and PARK7 differed most strongly by AD status, providing strong positive controls for our approach. CSF proteome changes in Alzheimer's disease prove to be widespread and often correlated with tau concentrations. Our unbiased screen also reveals a consistent glycolytic signature across our cohorts and a recent study. Machine learning suggests clinical utility of this proteomic signature.
Collapse
Affiliation(s)
- Jakob M Bader
- Department of Proteomics and Signal TransductionMax Planck Institute of BiochemistryMartinsriedGermany
| | - Philipp E Geyer
- Department of Proteomics and Signal TransductionMax Planck Institute of BiochemistryMartinsriedGermany
- NNF Center for Protein ResearchFaculty of Health SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Johannes B Müller
- Department of Proteomics and Signal TransductionMax Planck Institute of BiochemistryMartinsriedGermany
| | - Maximilian T Strauss
- Department of Proteomics and Signal TransductionMax Planck Institute of BiochemistryMartinsriedGermany
| | - Manja Koch
- Departments of Nutrition & EpidemiologyHarvard T.H. Chan School of Public HealthBostonMAUSA
| | - Frank Leypoldt
- Institute of Clinical ChemistryFaculty of MedicineKiel UniversityKielGermany
- Department of NeurologyFaculty of MedicineKiel UniversityKielGermany
| | - Peter Koertvelyessy
- Department of NeurologyMedical FacultyOtto von Guericke University MagdeburgMagdeburgGermany
- Department of NeurologyCharité Universitätsmedizin BerlinBerlinGermany
| | - Daniel Bittner
- Department of NeurologyMedical FacultyOtto von Guericke University MagdeburgMagdeburgGermany
| | - Carola G Schipke
- Experimental & Clinical Research Center (ECRC), Charité – Universitätsmedizin Berlincorporate member of Freie Universität BerlinHumboldt‐Universität zu Berlin, & Berlin Institute of HealthBerlinGermany
| | - Enise I Incesoy
- Department of Psychiatrycorporate member of Freie Universität Berlin, Humboldt‐Universität zu Berlin & Berlin Institute of Health, Charité Universitätsmedizin BerlinBerlinGermany
| | - Oliver Peters
- Department of Psychiatrycorporate member of Freie Universität Berlin, Humboldt‐Universität zu Berlin & Berlin Institute of Health, Charité Universitätsmedizin BerlinBerlinGermany
- German Center for Neurodegenerative DiseasesBerlinGermany
| | - Nikolaus Deigendesch
- Institute of Medical Genetics and PathologyUniversity Hospital BaselBaselSwitzerland
| | - Mikael Simons
- German Center for Neurodegenerative Diseases (DZNE)MunichGermany
- Munich Cluster for Systems NeurologyMunichGermany
| | - Majken K Jensen
- Departments of Nutrition & EpidemiologyHarvard T.H. Chan School of Public HealthBostonMAUSA
- Department of Public HealthUniversity of CopenhagenCopenhagenDenmark
| | - Henrik Zetterberg
- Department of Psychiatry and NeurochemistryInstitute of Neuroscience and Physiologythe Sahlgrenska Academy at the University of GothenburgMölndalSweden
- Clinical Neurochemistry LaboratorySahlgrenska University HospitalMölndalSweden
- UK Dementia Research Institute at UCLLondonUK
- Department of Neurodegenerative DiseaseUCL Institute of NeurologyLondonUK
| | - Matthias Mann
- Department of Proteomics and Signal TransductionMax Planck Institute of BiochemistryMartinsriedGermany
- NNF Center for Protein ResearchFaculty of Health SciencesUniversity of CopenhagenCopenhagenDenmark
| |
Collapse
|
8
|
Kork F, Jankowski J, Goswami A, Weis J, Brook G, Yamoah A, Anink J, Aronica E, Fritz S, Huck C, Schipke C, Peters O, Tepel M, Noels H, Jankowski V. Golgin A4 in CSF and granulovacuolar degenerations of patients with Alzheimer disease. Neurology 2018; 91:e1799-e1808. [PMID: 30305446 DOI: 10.1212/wnl.0000000000006457] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2017] [Accepted: 07/26/2018] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE To isolate and identify a new, as yet unknown molecule in CSF that could serve as marker for Alzheimer disease. METHODS We immunized mice with human CSF and fused hybridomas for monoclonal antibodies and screened these antibodies for their capacity to discriminate CSF of patients with Alzheimer disease from CSF of controls. We then chromatographically isolated the antigen to the best discriminating antibody and identified the antigen using mass spectrometric methods. Thereafter, we quantified the CSF concentration of the antigen in a new cohort of patients with Alzheimer disease and controls and performed immunohistochemistry of postmortem brain tissue derived from patients with Alzheimer disease and controls. RESULTS We generated >200 hybridomas and selected 1 antibody that discriminated CSF from patients with Alzheimer disease from that of controls. We identified golgin A4 as the antigen detected by this antibody. Golgin A4 concentration was significantly higher in CSF from patients with Alzheimer disease than in CSF of controls (145 [interquartile range 125-155] vs 115 [ 99-128] pg/mL, p < 0.001) and demonstrated a substantial discriminative power (area under the receiver operating characteristic curve 0.80, 95% confidence interval 0.67-0.94). Immunohistochemistry of postmortem brain sections from patients with Alzheimer disease revealed a significant accumulation of golgin A4 in granulovacuolar degeneration bodies (GVBs). CONCLUSIONS These results support the notion that golgin A4 could serve as a diagnostic marker in Alzheimer disease. For validation of this notion, prospective multicenter diagnostic studies will evaluate golgin A4 as diagnostic marker for Alzheimer disease. Furthermore, it has to be determined whether the association of golgin A4 with GVBs is an epiphenomenon or whether golgin A4 plays a more direct role in Alzheimer disease, allowing it to serve as a target in therapeutic treatment strategies. CLASSIFICATION OF EVIDENCE This study provides Class III evidence that elevated CSF golgin A4 levels identify patients with Alzheimer disease.
Collapse
Affiliation(s)
- Felix Kork
- From the Institute for Molecular Cardiovascular Research (F.K., J.J., H.N., V.J.), Department of Anesthesiology (F.K.), and Institute of Neuropathology (A.G., J.W., G.B., A.Y.), Medical Faculty, RWTH Aachen University, Germany; School for Cardiovascular Diseases (J.J.), Maastricht University; Department of (Neuro) Pathology (J.A., E.A.), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; mfd Diagnostics GmbH (S.F., C.H.), Wendelsheim; Charité-Universitätsmedizin Berlin (C.S., O.P.), corporate member of Freie Universität Berlin; Humboldt-Universität zu Berlin (C.S., O.P.); Berlin Institute of Health (C.S., O.P.), German Center for Neurodegenerative; Experimental and Clinical Research Center (C.S., O.P.), Memory Clinic, Berlin, Germany; and Department of Nephrology (M.T.), Odense University Hospital, Denmark
| | - Joachim Jankowski
- From the Institute for Molecular Cardiovascular Research (F.K., J.J., H.N., V.J.), Department of Anesthesiology (F.K.), and Institute of Neuropathology (A.G., J.W., G.B., A.Y.), Medical Faculty, RWTH Aachen University, Germany; School for Cardiovascular Diseases (J.J.), Maastricht University; Department of (Neuro) Pathology (J.A., E.A.), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; mfd Diagnostics GmbH (S.F., C.H.), Wendelsheim; Charité-Universitätsmedizin Berlin (C.S., O.P.), corporate member of Freie Universität Berlin; Humboldt-Universität zu Berlin (C.S., O.P.); Berlin Institute of Health (C.S., O.P.), German Center for Neurodegenerative; Experimental and Clinical Research Center (C.S., O.P.), Memory Clinic, Berlin, Germany; and Department of Nephrology (M.T.), Odense University Hospital, Denmark
| | - Anand Goswami
- From the Institute for Molecular Cardiovascular Research (F.K., J.J., H.N., V.J.), Department of Anesthesiology (F.K.), and Institute of Neuropathology (A.G., J.W., G.B., A.Y.), Medical Faculty, RWTH Aachen University, Germany; School for Cardiovascular Diseases (J.J.), Maastricht University; Department of (Neuro) Pathology (J.A., E.A.), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; mfd Diagnostics GmbH (S.F., C.H.), Wendelsheim; Charité-Universitätsmedizin Berlin (C.S., O.P.), corporate member of Freie Universität Berlin; Humboldt-Universität zu Berlin (C.S., O.P.); Berlin Institute of Health (C.S., O.P.), German Center for Neurodegenerative; Experimental and Clinical Research Center (C.S., O.P.), Memory Clinic, Berlin, Germany; and Department of Nephrology (M.T.), Odense University Hospital, Denmark
| | - Joachim Weis
- From the Institute for Molecular Cardiovascular Research (F.K., J.J., H.N., V.J.), Department of Anesthesiology (F.K.), and Institute of Neuropathology (A.G., J.W., G.B., A.Y.), Medical Faculty, RWTH Aachen University, Germany; School for Cardiovascular Diseases (J.J.), Maastricht University; Department of (Neuro) Pathology (J.A., E.A.), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; mfd Diagnostics GmbH (S.F., C.H.), Wendelsheim; Charité-Universitätsmedizin Berlin (C.S., O.P.), corporate member of Freie Universität Berlin; Humboldt-Universität zu Berlin (C.S., O.P.); Berlin Institute of Health (C.S., O.P.), German Center for Neurodegenerative; Experimental and Clinical Research Center (C.S., O.P.), Memory Clinic, Berlin, Germany; and Department of Nephrology (M.T.), Odense University Hospital, Denmark
| | - Gary Brook
- From the Institute for Molecular Cardiovascular Research (F.K., J.J., H.N., V.J.), Department of Anesthesiology (F.K.), and Institute of Neuropathology (A.G., J.W., G.B., A.Y.), Medical Faculty, RWTH Aachen University, Germany; School for Cardiovascular Diseases (J.J.), Maastricht University; Department of (Neuro) Pathology (J.A., E.A.), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; mfd Diagnostics GmbH (S.F., C.H.), Wendelsheim; Charité-Universitätsmedizin Berlin (C.S., O.P.), corporate member of Freie Universität Berlin; Humboldt-Universität zu Berlin (C.S., O.P.); Berlin Institute of Health (C.S., O.P.), German Center for Neurodegenerative; Experimental and Clinical Research Center (C.S., O.P.), Memory Clinic, Berlin, Germany; and Department of Nephrology (M.T.), Odense University Hospital, Denmark
| | - Alfred Yamoah
- From the Institute for Molecular Cardiovascular Research (F.K., J.J., H.N., V.J.), Department of Anesthesiology (F.K.), and Institute of Neuropathology (A.G., J.W., G.B., A.Y.), Medical Faculty, RWTH Aachen University, Germany; School for Cardiovascular Diseases (J.J.), Maastricht University; Department of (Neuro) Pathology (J.A., E.A.), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; mfd Diagnostics GmbH (S.F., C.H.), Wendelsheim; Charité-Universitätsmedizin Berlin (C.S., O.P.), corporate member of Freie Universität Berlin; Humboldt-Universität zu Berlin (C.S., O.P.); Berlin Institute of Health (C.S., O.P.), German Center for Neurodegenerative; Experimental and Clinical Research Center (C.S., O.P.), Memory Clinic, Berlin, Germany; and Department of Nephrology (M.T.), Odense University Hospital, Denmark
| | - Jasper Anink
- From the Institute for Molecular Cardiovascular Research (F.K., J.J., H.N., V.J.), Department of Anesthesiology (F.K.), and Institute of Neuropathology (A.G., J.W., G.B., A.Y.), Medical Faculty, RWTH Aachen University, Germany; School for Cardiovascular Diseases (J.J.), Maastricht University; Department of (Neuro) Pathology (J.A., E.A.), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; mfd Diagnostics GmbH (S.F., C.H.), Wendelsheim; Charité-Universitätsmedizin Berlin (C.S., O.P.), corporate member of Freie Universität Berlin; Humboldt-Universität zu Berlin (C.S., O.P.); Berlin Institute of Health (C.S., O.P.), German Center for Neurodegenerative; Experimental and Clinical Research Center (C.S., O.P.), Memory Clinic, Berlin, Germany; and Department of Nephrology (M.T.), Odense University Hospital, Denmark
| | - Eleonora Aronica
- From the Institute for Molecular Cardiovascular Research (F.K., J.J., H.N., V.J.), Department of Anesthesiology (F.K.), and Institute of Neuropathology (A.G., J.W., G.B., A.Y.), Medical Faculty, RWTH Aachen University, Germany; School for Cardiovascular Diseases (J.J.), Maastricht University; Department of (Neuro) Pathology (J.A., E.A.), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; mfd Diagnostics GmbH (S.F., C.H.), Wendelsheim; Charité-Universitätsmedizin Berlin (C.S., O.P.), corporate member of Freie Universität Berlin; Humboldt-Universität zu Berlin (C.S., O.P.); Berlin Institute of Health (C.S., O.P.), German Center for Neurodegenerative; Experimental and Clinical Research Center (C.S., O.P.), Memory Clinic, Berlin, Germany; and Department of Nephrology (M.T.), Odense University Hospital, Denmark
| | - Stefan Fritz
- From the Institute for Molecular Cardiovascular Research (F.K., J.J., H.N., V.J.), Department of Anesthesiology (F.K.), and Institute of Neuropathology (A.G., J.W., G.B., A.Y.), Medical Faculty, RWTH Aachen University, Germany; School for Cardiovascular Diseases (J.J.), Maastricht University; Department of (Neuro) Pathology (J.A., E.A.), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; mfd Diagnostics GmbH (S.F., C.H.), Wendelsheim; Charité-Universitätsmedizin Berlin (C.S., O.P.), corporate member of Freie Universität Berlin; Humboldt-Universität zu Berlin (C.S., O.P.); Berlin Institute of Health (C.S., O.P.), German Center for Neurodegenerative; Experimental and Clinical Research Center (C.S., O.P.), Memory Clinic, Berlin, Germany; and Department of Nephrology (M.T.), Odense University Hospital, Denmark
| | - Carmen Huck
- From the Institute for Molecular Cardiovascular Research (F.K., J.J., H.N., V.J.), Department of Anesthesiology (F.K.), and Institute of Neuropathology (A.G., J.W., G.B., A.Y.), Medical Faculty, RWTH Aachen University, Germany; School for Cardiovascular Diseases (J.J.), Maastricht University; Department of (Neuro) Pathology (J.A., E.A.), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; mfd Diagnostics GmbH (S.F., C.H.), Wendelsheim; Charité-Universitätsmedizin Berlin (C.S., O.P.), corporate member of Freie Universität Berlin; Humboldt-Universität zu Berlin (C.S., O.P.); Berlin Institute of Health (C.S., O.P.), German Center for Neurodegenerative; Experimental and Clinical Research Center (C.S., O.P.), Memory Clinic, Berlin, Germany; and Department of Nephrology (M.T.), Odense University Hospital, Denmark
| | - Carola Schipke
- From the Institute for Molecular Cardiovascular Research (F.K., J.J., H.N., V.J.), Department of Anesthesiology (F.K.), and Institute of Neuropathology (A.G., J.W., G.B., A.Y.), Medical Faculty, RWTH Aachen University, Germany; School for Cardiovascular Diseases (J.J.), Maastricht University; Department of (Neuro) Pathology (J.A., E.A.), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; mfd Diagnostics GmbH (S.F., C.H.), Wendelsheim; Charité-Universitätsmedizin Berlin (C.S., O.P.), corporate member of Freie Universität Berlin; Humboldt-Universität zu Berlin (C.S., O.P.); Berlin Institute of Health (C.S., O.P.), German Center for Neurodegenerative; Experimental and Clinical Research Center (C.S., O.P.), Memory Clinic, Berlin, Germany; and Department of Nephrology (M.T.), Odense University Hospital, Denmark
| | - Oliver Peters
- From the Institute for Molecular Cardiovascular Research (F.K., J.J., H.N., V.J.), Department of Anesthesiology (F.K.), and Institute of Neuropathology (A.G., J.W., G.B., A.Y.), Medical Faculty, RWTH Aachen University, Germany; School for Cardiovascular Diseases (J.J.), Maastricht University; Department of (Neuro) Pathology (J.A., E.A.), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; mfd Diagnostics GmbH (S.F., C.H.), Wendelsheim; Charité-Universitätsmedizin Berlin (C.S., O.P.), corporate member of Freie Universität Berlin; Humboldt-Universität zu Berlin (C.S., O.P.); Berlin Institute of Health (C.S., O.P.), German Center for Neurodegenerative; Experimental and Clinical Research Center (C.S., O.P.), Memory Clinic, Berlin, Germany; and Department of Nephrology (M.T.), Odense University Hospital, Denmark
| | - Martin Tepel
- From the Institute for Molecular Cardiovascular Research (F.K., J.J., H.N., V.J.), Department of Anesthesiology (F.K.), and Institute of Neuropathology (A.G., J.W., G.B., A.Y.), Medical Faculty, RWTH Aachen University, Germany; School for Cardiovascular Diseases (J.J.), Maastricht University; Department of (Neuro) Pathology (J.A., E.A.), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; mfd Diagnostics GmbH (S.F., C.H.), Wendelsheim; Charité-Universitätsmedizin Berlin (C.S., O.P.), corporate member of Freie Universität Berlin; Humboldt-Universität zu Berlin (C.S., O.P.); Berlin Institute of Health (C.S., O.P.), German Center for Neurodegenerative; Experimental and Clinical Research Center (C.S., O.P.), Memory Clinic, Berlin, Germany; and Department of Nephrology (M.T.), Odense University Hospital, Denmark
| | - Heidi Noels
- From the Institute for Molecular Cardiovascular Research (F.K., J.J., H.N., V.J.), Department of Anesthesiology (F.K.), and Institute of Neuropathology (A.G., J.W., G.B., A.Y.), Medical Faculty, RWTH Aachen University, Germany; School for Cardiovascular Diseases (J.J.), Maastricht University; Department of (Neuro) Pathology (J.A., E.A.), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; mfd Diagnostics GmbH (S.F., C.H.), Wendelsheim; Charité-Universitätsmedizin Berlin (C.S., O.P.), corporate member of Freie Universität Berlin; Humboldt-Universität zu Berlin (C.S., O.P.); Berlin Institute of Health (C.S., O.P.), German Center for Neurodegenerative; Experimental and Clinical Research Center (C.S., O.P.), Memory Clinic, Berlin, Germany; and Department of Nephrology (M.T.), Odense University Hospital, Denmark
| | - Vera Jankowski
- From the Institute for Molecular Cardiovascular Research (F.K., J.J., H.N., V.J.), Department of Anesthesiology (F.K.), and Institute of Neuropathology (A.G., J.W., G.B., A.Y.), Medical Faculty, RWTH Aachen University, Germany; School for Cardiovascular Diseases (J.J.), Maastricht University; Department of (Neuro) Pathology (J.A., E.A.), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands; mfd Diagnostics GmbH (S.F., C.H.), Wendelsheim; Charité-Universitätsmedizin Berlin (C.S., O.P.), corporate member of Freie Universität Berlin; Humboldt-Universität zu Berlin (C.S., O.P.); Berlin Institute of Health (C.S., O.P.), German Center for Neurodegenerative; Experimental and Clinical Research Center (C.S., O.P.), Memory Clinic, Berlin, Germany; and Department of Nephrology (M.T.), Odense University Hospital, Denmark.
| |
Collapse
|
9
|
Schipke CG, De Vos A, Fuentes M, Jacobs D, Vanmechelen E, Peters O. Neurogranin and BACE1 in CSF as Potential Biomarkers Differentiating Depression with Cognitive Deficits from Early Alzheimer's Disease: A Pilot Study. Dement Geriatr Cogn Dis Extra 2018; 8:277-289. [PMID: 30186306 PMCID: PMC6120408 DOI: 10.1159/000489847] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2018] [Accepted: 05/04/2018] [Indexed: 12/20/2022] Open
Abstract
Background/Aims Major depressive disorder (MDD) can cooccur with early Alzheimer's disease (AD) or may cause memory problems independently of AD. Previous studies have suggested that the AD-related cerebrospinal fluid (CSF) biomarkers tau and Aβ(1–42) could help discriminate between early AD and depression unrelated to AD. Moreover, the postsynaptic protein neurogranin and presynaptic BACE1 have increasingly gained attention as potential new AD biomarkers, but they have not yet been investigated concerning depression. Methods Using ELISAs, we studied CSF neurogranin and BACE1 levels in patients with mild (n = 21) and moderate (n = 19) AD, as well as in MDD patients with (n = 20) and without (n = 20) cognitive deficits. The clinical examinations included analyses of t-tau, Aβ(1–42), and Aβ(1–40), besides neuropsychological tests and cranial magnetic resonance imaging. Depressive symptom severity was assessed using the Geriatric Depression Scale (GDS). Results Along with classic AD biomarkers, neurogranin and BACE1 CSF levels differed between moderate AD and MDD (p ≤ 0.01). MDD associated with cognitive deficits was distinguished from mild AD through the CSF neurogranin/BACE1 ratio (p < 0.05), which was strongly correlated with GDS scores (ρ = −0.656; p < 0.01). Conclusion The neurogranin/BACE1 ratio in CSF can distinguish between depression and AD among patients with similar cognitive deficits, along with the classic AD biomarkers. Further longitudinal studies are ongoing to identify which biomarkers have prognostic value.
Collapse
Affiliation(s)
- Carola G Schipke
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Neuropathology, Berlin, Germany
| | | | - Manuel Fuentes
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH) and German Center for Neurodegenerative Diseases (DZNE), Department of Psychiatry and Psychotherapy, Berlin, Germany
| | - Dirk Jacobs
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Neuropathology, Berlin, Germany
| | - Eugeen Vanmechelen
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH), Neuropathology, Berlin, Germany
| | - Oliver Peters
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health (BIH) and German Center for Neurodegenerative Diseases (DZNE), Department of Psychiatry and Psychotherapy, Berlin, Germany.,German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
| |
Collapse
|
10
|
Derkow K, Rössling R, Schipke C, Krüger C, Bauer J, Fähling M, Stroux A, Schott E, Ruprecht K, Peters O, Lehnardt S. Distinct expression of the neurotoxic microRNA family let-7 in the cerebrospinal fluid of patients with Alzheimer's disease. PLoS One 2018; 13:e0200602. [PMID: 30011310 PMCID: PMC6047809 DOI: 10.1371/journal.pone.0200602] [Citation(s) in RCA: 75] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Accepted: 07/01/2018] [Indexed: 12/20/2022] Open
Abstract
MicroRNAs (miRNAs) are non-coding RNAs originally involved in RNA silencing and post-transcriptional regulation of gene expression. We have shown in previous work that the miRNA let-7b can act as a signalling molecule for Toll-like receptor 7, thereby initiating innate immune pathways and apoptosis in the central nervous system. Here, we investigated whether different members of the miRNA family let-7, abundantly expressed in the brain, are released into the human cerebrospinal fluid (CSF) and whether quantitative differences in let-7 copies exist in neurodegenerative diseases. RNA isolated from CSF of patients with Alzheimer´s disease (AD) and from control patients with frontotemporal lobe dementia (FTLD), major depressive episode (MDE) without clinical or neurobiological signs of AD, and healthy individuals, was reverse transcribed with primers against nine let-7 family members, and miRNAs were quantified and analyzed comparatively by quantitative PCR. let-7 miRNAs were present in CSF from patients with AD, FTLD, MDE, and healthy controls. However, the amount of individual let-7 miRNAs in the CSF varied substantially. CSF from AD patients contained higher amounts of let-7b and let-7e compared to healthy controls, while no differences were observed regarding the other let-7 miRNAs. No increase in let-7b and let-7e was detected in CSF from FTLD patients, while in CSF from MDE patients, let-7b and let-7e copy levels were elevated. In CSF from AD patients, let-7b and let-7e were associated with extracellular vesicles. let-7 family members present in the CSF mediated neurotoxicity in vitro, albeit to a variable extent. Taken together, neurotoxic let-7 miRNAs are differentially and specifically released in AD, but also in MDE patients. Thus, these miRNAs may mirror common neuropathological paths and by this serve to unscramble mechanisms of different neurodegenerative diseases.
Collapse
Affiliation(s)
- Katja Derkow
- Institute of Cell Biology and Neurobiology, Center for Anatomy, Charité - Universitaetsmedizin Berlin, Berlin, Germany
| | - Rosa Rössling
- Institute of Cell Biology and Neurobiology, Center for Anatomy, Charité - Universitaetsmedizin Berlin, Berlin, Germany
| | - Carola Schipke
- Institute of Neuropathology, Charité - Universitaetsmedizin Berlin, Berlin, Germany
| | - Christina Krüger
- Institute of Cell Biology and Neurobiology, Center for Anatomy, Charité - Universitaetsmedizin Berlin, Berlin, Germany
| | - Jakob Bauer
- Institute of Cell Biology and Neurobiology, Center for Anatomy, Charité - Universitaetsmedizin Berlin, Berlin, Germany
| | - Michael Fähling
- Institute of Vegetative Physiology, Charité - Universitaetsmedizin Berlin, Berlin, Germany
| | - Andrea Stroux
- Institute for Biometry and Clinical Epidemiology, Charité - Universitaetsmedizin Berlin / Berlin Institute of health (BIH), Berlin, Germany
| | - Eckart Schott
- Department of Hepatology and Gastroenterology, Charité - Universitaetsmedizin Berlin, Berlin, Germany
| | - Klemens Ruprecht
- Department of Neurology, Charité - Universitaetsmedizin Berlin, Berlin, Germany
| | - Oliver Peters
- Department of Psychiatry, Charité - Universitaetsmedizin Berlin, Berlin, Germany
- German Center for Neurodegenerative Diseases (DZNE), Charité - Universitaetsmedizin Berlin, Berlin, Germany
| | - Seija Lehnardt
- Institute of Cell Biology and Neurobiology, Center for Anatomy, Charité - Universitaetsmedizin Berlin, Berlin, Germany
- Department of Neurology, Charité - Universitaetsmedizin Berlin, Berlin, Germany
- Cluster of Excellence NeuroCure, Charité - Universitaetsmedizin Berlin, Berlin, Germany
- * E-mail:
| |
Collapse
|
11
|
Schipke CG, Koglin N, Bullich S, Joachim LK, Haas B, Seibyl J, Barthel H, Sabri O, Peters O. Correlation of florbetaben PET imaging and the amyloid peptide Aß42 in cerebrospinal fluid. Psychiatry Res Neuroimaging 2017; 265:98-101. [PMID: 28024844 DOI: 10.1016/j.pscychresns.2016.10.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2016] [Revised: 10/27/2016] [Accepted: 10/28/2016] [Indexed: 01/26/2023]
Abstract
Today, the use of biomarkers such as amyloid-specific positron emission tomography (PET) tracers and information derived from cerebrospinal fluid (CSF) can support the diagnosis of Alzheimer's disease (AD) as an indicator for the presence of amyloid pathology. We here show that the PET signal of the 18F-labelled tracer florbetaben (NeuraCeq™), that binds to amyloid-beta plaques, inversely correlates with CSF levels of Aß42, another biomarker for AD. Results from the two biomarkers were concordant in 35 out of 38 subjects. In 7 AD subjects (20%) at least one biomarker was inconsistent with the clinical diagnosis. This confirms known limitations of the clinical AD diagnosis and highlights the potential of biomarker-assisted diagnosis to improve accuracy.
Collapse
Affiliation(s)
- Carola G Schipke
- Charité-Universitätsmedizin Berlin, Experimental and Clinical Research Center - ECRC, Berlin, Germany; Charité-Universitätsmedizin Berlin, Institute of Neuropathology, Berlin, Germany.
| | | | | | | | - Brigitte Haas
- Charité-Universitätsmedizin Berlin, Experimental and Clinical Research Center - ECRC, Berlin, Germany; Department of Psychiatry, Charité-Campus Benjamin Franklin, Berlin, Germany
| | - John Seibyl
- Molecular NeuroImaging, LLC (MNI), New Haven, CT, USA
| | - Henryk Barthel
- Leipzig University, Department of Nuclear Medicine, Leipzig, Germany
| | - Osama Sabri
- Leipzig University, Department of Nuclear Medicine, Leipzig, Germany
| | - Oliver Peters
- Charité-Universitätsmedizin Berlin, Experimental and Clinical Research Center - ECRC, Berlin, Germany; Department of Psychiatry, Charité-Campus Benjamin Franklin, Berlin, Germany
| |
Collapse
|
12
|
Fá M, Puzzo D, Piacentini R, Staniszewski A, Zhang H, Baltrons MA, Li Puma DD, Chatterjee I, Li J, Saeed F, Berman HL, Ripoli C, Gulisano W, Gonzalez J, Tian H, Costa JA, Lopez P, Davidowitz E, Yu WH, Haroutunian V, Brown LM, Palmeri A, Sigurdsson EM, Duff KE, Teich AF, Honig LS, Sierks M, Moe JG, D'Adamio L, Grassi C, Kanaan NM, Fraser PE, Arancio O. Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. Sci Rep 2016; 6:19393. [PMID: 26786552 PMCID: PMC4726138 DOI: 10.1038/srep19393] [Citation(s) in RCA: 197] [Impact Index Per Article: 24.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Accepted: 10/07/2015] [Indexed: 12/21/2022] Open
Abstract
Non-fibrillar soluble oligomeric forms of amyloid-β peptide (oAβ) and tau proteins are likely to play a major role in Alzheimer's disease (AD). The prevailing hypothesis on the disease etiopathogenesis is that oAβ initiates tau pathology that slowly spreads throughout the medial temporal cortex and neocortices independently of Aβ, eventually leading to memory loss. Here we show that a brief exposure to extracellular recombinant human tau oligomers (oTau), but not monomers, produces an impairment of long-term potentiation (LTP) and memory, independent of the presence of high oAβ levels. The impairment is immediate as it raises as soon as 20 min after exposure to the oligomers. These effects are reproduced either by oTau extracted from AD human specimens, or naturally produced in mice overexpressing human tau. Finally, we found that oTau could also act in combination with oAβ to produce these effects, as sub-toxic doses of the two peptides combined lead to LTP and memory impairment. These findings provide a novel view of the effects of tau and Aβ on memory loss, offering new therapeutic opportunities in the therapy of AD and other neurodegenerative diseases associated with Aβ and tau pathology.
Collapse
Affiliation(s)
- M Fá
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, 630 W 168th St. New York, NY 10032 USA
| | - D Puzzo
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, 630 W 168th St. New York, NY 10032 USA.,Department of Biomedical and Biotechnological Sciences, Section of Physiology, University of Catania, Catania, 95125 Italy
| | - R Piacentini
- Institute of Human Physiology, Università Cattolica del Sacro Cuore, Rome, 00168 Italy
| | - A Staniszewski
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, 630 W 168th St. New York, NY 10032 USA
| | - H Zhang
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, 630 W 168th St. New York, NY 10032 USA
| | - M A Baltrons
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, 630 W 168th St. New York, NY 10032 USA.,Department of Biochemistry and Molecular Biology, Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona, Bellaterra, 08193, Spain
| | - D D Li Puma
- Institute of Human Physiology, Università Cattolica del Sacro Cuore, Rome, 00168 Italy
| | - I Chatterjee
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, 630 W 168th St. New York, NY 10032 USA.,Oligomerix, Inc., Oligomerix, Inc., 7 Legion Drive, Suite 101, Valhalla, NY 10595, USA
| | - J Li
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, 630 W 168th St. New York, NY 10032 USA.,Department of Neurology, Third Military Medical University, Chongqing, 400042, China
| | - F Saeed
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, 630 W 168th St. New York, NY 10032 USA
| | - H L Berman
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, 630 W 168th St. New York, NY 10032 USA
| | - C Ripoli
- Institute of Human Physiology, Università Cattolica del Sacro Cuore, Rome, 00168 Italy
| | - W Gulisano
- Department of Biomedical and Biotechnological Sciences, Section of Physiology, University of Catania, Catania, 95125 Italy
| | - J Gonzalez
- Translational Technology Core Laboratory, Rockefeller University, New York, NY 10065, USA
| | - H Tian
- Department of Chemical Engineering, ASU, Tempe, AZ 85281, USA
| | - J A Costa
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, 630 W 168th St. New York, NY 10032 USA
| | - P Lopez
- Oligomerix, Inc., Oligomerix, Inc., 7 Legion Drive, Suite 101, Valhalla, NY 10595, USA
| | - E Davidowitz
- Oligomerix, Inc., Oligomerix, Inc., 7 Legion Drive, Suite 101, Valhalla, NY 10595, USA
| | - W H Yu
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, 630 W 168th St. New York, NY 10032 USA
| | - V Haroutunian
- Department of Psychiatry, The Mount Sinai School of Medicine, JJ-Peters VA Medical Center, Bronx, NY 10468, USA
| | - L M Brown
- Department of Biological Sciences, Columbia University, New York, NY 10027, USA
| | - A Palmeri
- Department of Biomedical and Biotechnological Sciences, Section of Physiology, University of Catania, Catania, 95125 Italy
| | - E M Sigurdsson
- Department of Neuroscience and Physiology, NYU Langone Medical Center, New York, NY 10016, USA
| | - K E Duff
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, 630 W 168th St. New York, NY 10032 USA
| | - A F Teich
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, 630 W 168th St. New York, NY 10032 USA
| | - L S Honig
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, 630 W 168th St. New York, NY 10032 USA
| | - M Sierks
- Translational Technology Core Laboratory, Rockefeller University, New York, NY 10065, USA
| | - J G Moe
- Oligomerix, Inc., Oligomerix, Inc., 7 Legion Drive, Suite 101, Valhalla, NY 10595, USA
| | - L D'Adamio
- Department of Microbiology and Immunology, Einstein College of Medicine, Bronx, NY 10461, USA
| | - C Grassi
- Institute of Human Physiology, Università Cattolica del Sacro Cuore, Rome, 00168 Italy.,San Raffaele Pisana Scientific Institute for Research, Hospitalization and Health Care, Rome, 00163, Italy
| | - N M Kanaan
- Department of Translational Science and Molecular Medicine, College of Human Medicine, MSU, Grand Rapids, MI, 49503, USA
| | - P E Fraser
- Tanz Centre for Research in Neurodegenerative Diseases and Department of Medical Biophysics, University of Toronto, 60 Leonard Avenue, Toronto, Ontario M5T 2S8 Toronto, Canada
| | - O Arancio
- Department of Pathology and Cell Biology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University, 630 W 168th St. New York, NY 10032 USA
| |
Collapse
|
13
|
Fourier A, Portelius E, Zetterberg H, Blennow K, Quadrio I, Perret-Liaudet A. Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability. Clin Chim Acta 2015; 449:9-15. [PMID: 26141614 DOI: 10.1016/j.cca.2015.05.024] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2015] [Accepted: 05/30/2015] [Indexed: 12/24/2022]
Abstract
A panel of cerebrospinal fluid (CSF) biomarkers including total Tau (t-Tau), phosphorylated Tau protein at residue 181 (p-Tau) and β-amyloid peptides (Aβ42 and Aβ40), is frequently used as an aid in Alzheimer's disease (AD) diagnosis for young patients with cognitive impairment, for predicting prodromal AD in mild cognitive impairment (MCI) subjects, for AD discrimination in atypical clinical phenotypes and for inclusion/exclusion and stratification of patients in clinical trials. Due to variability in absolute levels between laboratories, there is no consensus on medical cut-off value for the CSF AD signature. Thus, for full implementation of this core AD biomarker panel in clinical routine, this issue has to be solved. Variability can be explained both by pre-analytical and analytical factors. For example, the plastic tubes used for CSF collection and storage, the lack of reference material and the variability of the analytical protocols were identified as important sources of variability. The aim of this review is to highlight these pre-analytical and analytical factors and describe efforts done to counteract them in order to establish cut-off values for core CSF AD biomarkers. This review will give the current state of recommendations.
Collapse
Affiliation(s)
- Anthony Fourier
- Neurobiology Laboratory, Biochemistry and Molecular Biology Department, Hôpitaux de Lyon, Lyon, France; University of Lyon 1, CNRS UMR5292, INSERM U1028, BioRan, Lyon, France
| | - Erik Portelius
- Clinical, Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Sweden
| | - Henrik Zetterberg
- Clinical, Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Sweden; Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK
| | - Kaj Blennow
- Clinical, Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Sweden
| | - Isabelle Quadrio
- Neurobiology Laboratory, Biochemistry and Molecular Biology Department, Hôpitaux de Lyon, Lyon, France; University of Lyon 1, CNRS UMR5292, INSERM U1028, BioRan, Lyon, France
| | - Armand Perret-Liaudet
- Neurobiology Laboratory, Biochemistry and Molecular Biology Department, Hôpitaux de Lyon, Lyon, France; University of Lyon 1, CNRS UMR5292, INSERM U1028, BioRan, Lyon, France; Société Française de Biologie Clinique (SFBC), Alzheimer Biomarkers group co-coordination, France.
| |
Collapse
|
14
|
Delaby C, Gabelle A, Meynier P, Loubiere V, Vialaret J, Tiers L, Ducos J, Hirtz C, Lehmann S. Development and validation of dried matrix spot sampling for the quantitative determination of amyloid β peptides in cerebrospinal fluid. Clin Chem Lab Med 2014; 52:649-55. [PMID: 24150208 DOI: 10.1515/cclm-2013-0611] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2013] [Accepted: 09/30/2013] [Indexed: 11/15/2022]
Abstract
BACKGROUND The use of dried blood spots on filter paper is well documented as an affordable and practical alternative to classical venous sampling for various clinical needs. This technique has indeed many advantages in terms of collection, biological safety, storage, and shipment. Amyloid β (Aβ) peptides are useful cerebrospinal fluid (CSF) biomarkers for Alzheimer disease diagnosis. However, Aβ determination is hindered by preanalytical difficulties in terms of sample collection and stability in tubes. METHODS We compared the quantification of Aβ peptides (1-40, 1-42, and 1-38) by simplex and multiplex ELISA, following either a standard operator method (liquid direct quantification) or after spotting CSF onto dried matrix paper card. RESULTS The use of dried matrix spot (DMS) overcame preanalytical problems and allowed the determination of Aβ concentrations that were highly commutable (Bland-Altman) with those obtained using CSF in classical tubes. Moreover, we found a positive and significant correlation (r2=0.83, Pearson coefficient p=0.0329) between the two approaches. CONCLUSIONS This new DMS method for CSF represents an interesting alternative that increases the quality and efficiency in preanalytics. This should enable the better exploitation of Aβ analytes for Alzheimer's diagnosis.
Collapse
|
15
|
The use of multiplex platforms for absolute and relative protein quantification of clinical material. EUPA OPEN PROTEOMICS 2014. [DOI: 10.1016/j.euprot.2014.02.002] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
16
|
Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat Med 2012. [PMID: 23178247 DOI: 10.1038/nm.2965] [Citation(s) in RCA: 292] [Impact Index Per Article: 24.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The pathology of Alzheimer's disease has an inflammatory component that is characterized by upregulation of proinflammatory cytokines, particularly in response to amyloid-β (Aβ). Using the APPPS1 Alzheimer's disease mouse model, we found increased production of the common interleukin-12 (IL-12) and IL-23 subunit p40 by microglia. Genetic ablation of the IL-12/IL-23 signaling molecules p40, p35 or p19, in which deficiency of p40 or its receptor complex had the strongest effect, resulted in decreased cerebral amyloid load. Although deletion of IL-12/IL-23 signaling from the radiation-resistant glial compartment of the brain was most efficient in mitigating cerebral amyloidosis, peripheral administration of a neutralizing p40-specific antibody likewise resulted in a reduction of cerebral amyloid load in APPPS1 mice. Furthermore, intracerebroventricular delivery of antibodies to p40 significantly reduced the concentration of soluble Aβ species and reversed cognitive deficits in aged APPPS1 mice. The concentration of p40 was also increased in the cerebrospinal fluid of subjects with Alzheimer's disease, which suggests that inhibition of the IL-12/IL-23 pathway may attenuate Alzheimer's disease pathology and cognitive deficits.
Collapse
|
17
|
Regeniter A, Kuhle J, Baumann T, Sollberger M, Herdener M, Kunze U, Camuso MC, Monsch AU. Biomarkers of dementia: comparison of electrochemiluminescence results and reference ranges with conventional ELISA. Methods 2012; 56:494-9. [PMID: 22503775 DOI: 10.1016/j.ymeth.2012.03.019] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2012] [Revised: 03/04/2012] [Accepted: 03/09/2012] [Indexed: 10/28/2022] Open
Abstract
We compared the performance of the Meso Scale Diagnostics electrochemiluminescence (MSD) multiplex assay for t-tau and p-tau(231), originally developed for measurement of brain cell extract and tissue cultures, with the established standard method, the Innogenetics ELISA for total and p-tau(181). The methods were also clinically evaluated with 120 samples from our mono center population. The established Innogenetics ELISA procedures have been well optimized to measure patient samples in the normal and pathological range. Compared to the MSD they were superior in the limit of detection for total as well as p-tau. The obtained reference values for our normal controls were in the upper third of the published studies. Innogenetics tau, Innogenetics p-tau(181) and MSD t-tau differentiated the Alzheimer's (n=44) and minimal impairment group (MCI, n=39) from normal controls (n=37), but the MCI group was not statistically different from the normal controls. The MSD multiplex assay measured t-tau adequately but p-tau(231) could not differentiate normal from pathological results in CSF due to the high limit of detection. Both procedures however, have to be further standardized and complemented by adequate internal and external quality control schemes to qualify for routine analysis in a medical laboratory.
Collapse
Affiliation(s)
- Axel Regeniter
- Basel University Hospital, Dept. of Laboratory Medicine, Petersgraben 4, CH 4031 Basel, Switzerland.
| | | | | | | | | | | | | | | |
Collapse
|